DEA takes additional steps to allow increased production of controlled substances used in COVID-19 care
The Drug Enforcement Administration announced today that it is increasing Aggregate Production Quotas available to pharmaceutical manufacturers for the production of controlled substance medications that are in high demand due to the coronavirus (COVID-19) pandemic. DEA will also approve increases in imports of medications necessary for patients on ventilators.
Healthcare Supply of Personal Protective Equipment
CDC continues to monitor the COVID-19 situation in the United States and around the world. CDC has taken early and aggressive.